Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity

Tamoxifen is administered for estrogen receptor positive (ER(+)) breast cancers, but it can induce uterine endometrial cancer and non-alcoholic fatty liver disease (NAFLD). Importantly, ten years of tamoxifen treatment has greater protective effect against ER(+) breast cancer than five years of such...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Wenwen, Xu, Wenping, Sun, Xiaoxi, Zeng, Bubing, Wang, Shuangjie, Dong, Nian, Zhang, Xu, Chen, Chengshui, Yang, Long, Chen, Guowu, Xin, Aijie, Ni, Zhong, Wang, Jian, Yang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339706/
https://www.ncbi.nlm.nih.gov/pubmed/28266626
http://dx.doi.org/10.1038/srep43940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339706/
https://www.ncbi.nlm.nih.gov/pubmed/28266626
http://dx.doi.org/10.1038/srep43940

Ejemplares similares